Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms The nanobody was conjugated with the chelator NOTA and radiolabeled with 64Cu |
Target |
Action modulators, enhancers |
Mechanism CALR modulators(calreticulin modulators), PET imaging(Positron-emission tomography enhancers) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma | Preclinical | United States | 27 Apr 2025 | |
| Pancreatic Ductal Adenocarcinoma | Preclinical | United States | 27 Apr 2025 |






